Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-11 02:37:10 EDT

Explore

PostsPeople
LatestRanked
@biomedicines.bsky.socialOct 7, 2026, 9:02 AM

🧬 A novel lipopeptide suppressed both melanoma & psoriasis in immunocompetent mice. Findings suggest it may help balance anticancer immunity and immune tolerance, offering a potential new approach in cancer immunotherapy. ⚖️ #CancerImmunotherapy
www.mdpi.com/2227-9059/13...

@gmj-georgia.bsky.socialOct 1, 2026, 9:26 AM

🔬 mRNA cancer vaccines use an unexpected immune backup system that scientists didn't know about until now. This discovery could lead to… #Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcology #Vaccinedevelopment #Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcolog…

@uoustanford.bsky.socialSep 27, 2026, 2:21 PM

Orca-T represents a milestone in cancer research, making stem cell transplants safer for blood cancer patients by using the immune system with greater precision to open new possibilities across oncology.

Learn more: med.stanford.edu/cancer/about...

#StanfordMedicine #CancerImmunotherapy

@gmj-georgia.bsky.socialSep 24, 2026, 9:26 PM

New laboratory research reveals creatine may strengthen cancer-fighting immune pathways by energizing dendritic cells that activate killer T c… #Cancerimmunotherapy #Creatine #Dendriticcells #Immunemetabolism #Translationalresearch #Cancerimmunotherapy #Creatine #Dendriticcells #Immunemetabolis…

@gmj-georgia.bsky.socialSep 21, 2026, 5:26 PM

New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma… #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematolo…

@sigtrans-sttt.bsky.socialSep 21, 2026, 4:20 PM

Researchers evaluate the novel PARP inhibitor prodrug TSL-1502 in a phase 2 trial, demonstrating promising antitumor activity in BRCA-mutated HER2-negative advanced breast cancer. #ClinicalTrial

#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #CancerImmunotherapy

@gpbees.bsky.socialSep 21, 2026, 3:05 PM

6/ 💡 Together, the study expands the landscape of potential HCC antigens beyond the canonical proteome and provides a framework for discovering and validating ncORF-derived targets for cancer immunotherapy.

#LiverCancer #HCC #CancerImmunotherapy #Immunopeptidomics

@alicefrolov.bsky.socialSep 12, 2026, 5:18 PM

Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade.

#TcellExhaustion #CheckpointBlockade #TumorImmunology #CD8Tcells #AntiPD1 #Tpex #ImmuneCheckpoint #CancerImmunotherapy

Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade. Figure: "Reprogramming exhausted CD8+ T cells with anti-PD-1 therapy" Subtitle: "Marker-defined transitions from terminal exhaustion toward progenitor/effector states after checkpoint blockade" The visualization employs a faceted marginal-distribution slope arrow design, functioning as a state-transition flow map. Each facet corresponds to a defined exhaustion-associated marker axis (TCF1, TOX, TIM-3, PD-1, GZMB, and Ki-67), with paired marginal distributions rendered pre- and post-treatment. Slope arrows connect the density centroids across conditions, encoding both the directionality and relative magnitude of population-level marker shifts. This approach was chosen to make explicit the differential mobilization of progenitor-exhausted (Tpex) versus terminally exhausted (Tex_term) subsets rather than collapsing the transition into a single trajectory summary. The simulated data are calibrated to reproduce trends consistent with the current literature. Under anti-PD-1, the TCF1+ TOX-intermediate progenitor compartment shows expansion accompanied by upward slope vectors in Ki-67 and GZMB, consistent with proliferative burst and reacquisition of effector potential. Concurrently, the TIM-3-high, TCF1-negative terminally differentiated fraction contracts, and its centroid displays limited displacement along the TCF1 axis, reflecting the constrained plasticity of terminally exhausted cells. This asymmetry underscores that checkpoint blockade preferentially acts on the Tpex reservoir rather than fully reverting terminal exhaustion, a distinction with direct implications for durability of response.
@mdpipharma.bsky.socialSep 11, 2026, 10:27 AM

🧬 Natural product immunotherapies in 3D tumor models—penetration vs activity. This review says: don't chase depth, preserve activity at peripheral immune cells. New evaluation framework inside!

📌 www.mdpi.com/1999-4923/17...

#CancerImmunotherapy #NaturalProducts #3DModels

@genesndiseases.bsky.socialSep 11, 2026, 2:00 AM

Better #CancerImmunotherapy requires tackling hidden immune barriers.
This review highlights how dysfunctional #Bcells suppress anti-tumor immunity and outlines strategies to reprogram the #TumorMicroenvironment.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...

@jem.orgSep 11, 2026, 12:01 AM

The transcription factor IRF8 drives tumor-specific exhaustion in CD8⁺ T Cells. From Marco Ongaro, Grégory Verdeil and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@gmj-georgia.bsky.socialSep 10, 2026, 8:41 PM

New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma… #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematolo…

@sigtrans-sttt.bsky.socialSep 10, 2026, 11:45 AM

Which noncanonical tumor antigens can be translated into T-cell targets?

EVA003 emerges as a #Melanoma-enriched antigen whose HLA-A*03:01-presented peptide is recognized by a natural TCR that directs melanoma cell killing.

#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerImmunotherapy

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen
@jem.orgSep 10, 2026, 12:01 AM

Intravesical mesothelin-based #CARTcells targeting MUC16 effectively control #BladderCancer in preclinical models. From Parwiz Abrahimi, Renier Brentjens, Jedd Wolchok, Taha Merghoub et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 9, 2026, 3:00 AM

@ostendorflab.org, @immushuang.bsky.social, @sohailtavazoie.bsky.social et al. show that activation of LXRs elicits a T cell "pre-effector" state that enhances priming and promotes anti-tumor immunity. rupress.org/jem/article/...

In #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 9, 2026, 12:01 AM

CD1d remodels the tumor-infiltrating myeloid populations controlling anti-tumor immunity. From Lauren Evans, Maria Conde Poole, Patricia Barral @barrallab.bsky.social: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 8, 2026, 3:00 AM

Targeting Mettl8-Tcf1 axis promotes CD8⁺ TPEX differentiation and antitumor immunity. From Jiaxi Song, Dan Cui, Qizhao Huang, Jia Li, Fengyin Li, and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 8, 2026, 12:00 AM

Tumor-reactive LAG3⁺CD8⁺ T cells diverge into terminally exhausted cells and long-lived memory T cells. From Vaishali Aggarwal, Yangxi Sun, Chang Liu, Dario Vignali @vignalilab.bsky.social: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 7, 2026, 3:00 AM

PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity. From Shibo Liu, Guanghao Liang, Yayun Yang, Yanyang Shi, Lihui Dong, Peng R. Chen, Meng Michelle Xu et al.: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

@jem.orgSep 7, 2026, 12:00 AM

In this review, Almonte, Thomas, and Zitvogel highlight how the gut #microbiome modulates immune checkpoint blockade efficacy in #cancer. rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia

Load more